Sliding Hip Screwplate: Do you always biopsy hip metastases first?

Sliding Hip Screwplate: Do you always biopsy hip metastases first?

Introduction & Epidemiology

The sliding hip screwplate (SHS), particularly the dynamic hip screw (DHS) system, remains a fundamental implant in orthopedic trauma surgery, primarily for the stabilization of stable intertrochanteric hip fractures. Its biomechanical principle of controlled collapse, allowing for fracture impaction and load sharing, has demonstrated reliable outcomes for specific fracture patterns. However, its application extends beyond traumatic injuries to the management of pathologic fractures, where the considerations for diagnosis and prognosis add significant complexity to surgical decision-making.

Intertrochanteric fractures constitute a substantial portion, approximately 45-50%, of all hip fractures, with an increasing incidence linked to an aging population and rising prevalence of osteoporosis. These fractures are associated with significant morbidity and mortality, making effective surgical management crucial for restoring mobility and preventing complications.

Concurrently, bone metastases represent the most common malignancy of bone, significantly outnumbering primary bone tumors. The spine, pelvis, and proximal femur are among the most frequent sites for metastatic disease. Common primary cancers that metastasize to bone include breast, prostate, lung, kidney, and thyroid. Approximately 10-30% of patients with bone metastases will develop a pathologic fracture, with the proximal femur being a critical location due to its weight-bearing function. The presence of a pathologic fracture often indicates advanced disease, carries a poor prognosis for overall survival, and severely impairs quality of life due to pain and loss of ambulation.

The core dilemma addressed in this discussion revolves around the necessity and timing of biopsy for suspected or confirmed hip metastases presenting as an impending or actual pathologic fracture requiring SHS fixation. While definitive tissue diagnosis is paramount for guiding systemic oncologic therapy, the urgency of fracture stabilization, patient comorbidities, and the clinical context (e.g., known primary malignancy versus occult primary) significantly influence the pre-operative workup pathway. The decision to biopsy prior to fixation, intraoperatively, or to defer it, is a nuanced one that balances diagnostic imperative with surgical expediency and patient safety.

Surgical Anatomy & Biomechanics

Proximal Femoral Anatomy

A comprehensive understanding of the proximal femur is paramount for successful SHS application. Key anatomical landmarks include:
* Greater Trochanter: The most lateral prominence, providing attachment for gluteus medius and minimus. The entry point for the guide pin is typically inferior to its vastus ridge.
* Lesser Trochanter: A posteromedial prominence, providing insertion for the iliopsoas. Its integrity and involvement in fracture patterns are critical for stability.
* Intertrochanteric Line/Crest: Connects the greater and lesser trochanters anteriorly and posteriorly, respectively. These are the anatomical boundaries of intertrochanteric fractures.
* Calcar Femorale: A dense, vertically oriented cortical buttress extending from the posteromedial aspect of the femoral neck toward the lesser trochanter. It provides crucial medial support. Fractures involving or extending through the calcar can compromise stability and risk varus collapse.
* Femoral Head and Neck: The lag screw must be placed optimally within the femoral head, ideally in the central-inferior quadrant on an anteroposterior (AP) view and central on a lateral view, approximately 1 cm from the subchondral bone. This provides maximal bone purchase and avoids articular penetration.
* Blood Supply: The main blood supply to the femoral head comes from the medial and lateral circumflex femoral arteries, forming an extracapsular ring, with retinacular branches ascending along the femoral neck. While SHS fixation is generally extracapsular and less disruptive than intracapsular fixation, awareness of vascularity is important in the context of extensive tumor involvement or prior radiation.

Fracture Patterns Relevant to SHS

Intertrochanteric fractures are classified by the AO/OTA system, primarily as 31-A type fractures. SHS is generally indicated for stable and some unstable patterns:
* 31-A1 (Simple Two-Part): Stable fractures, often reverse oblique, where SHS can be considered, though IMN is often preferred for 31-A3.
* 31-A2 (Multifragmentary):
* 31-A2.1: Stable, involving the lesser trochanter. SHS is often suitable.
* 31-A2.2: Unstable, with posteromedial comminution (calcar involvement). SHS can be used if adequate reduction and impaction can be achieved, but careful consideration of screw position and bone quality is needed.
* 31-A2.3: Very unstable, with both posteromedial and lateral comminution. These are borderline for SHS and may be better managed with an intramedullary nail (IMN).
* 31-A3 (Reverse Obliquity): Unstable fractures where the fracture line runs from superomedial to inferolateral. These are generally contraindicated for SHS as the lateral cortex is in tension, leading to higher rates of cut-out and varus collapse. IMN is the preferred implant for 31-A3 fractures.

SHS Mechanics and Biomechanics

The SHS system consists of three main components:
1. Lag Screw (or Compression Screw): A large-diameter, fully threaded cannulated screw inserted across the fracture into the femoral head. It allows for controlled sliding within the barrel.
2. Side Plate: Attached to the lateral femoral cortex, with a barrel that accepts the lag screw.
3. Compression Screw (optional): Inserted into the lag screw to provide initial compression across the fracture site.

The fundamental biomechanical principle of SHS is controlled collapse and load sharing .
* Controlled Collapse: After insertion, the lag screw is free to slide within the barrel of the side plate. As the patient mobilizes and loads the hip, the femoral head fragment can impact onto the femoral shaft, dynamically compressing the fracture fragments. This impaction theoretically promotes fracture healing and reduces stress shielding.
* Load Sharing: The implant shares stress with the bone rather than entirely shielding it, which is thought to reduce the risk of implant fatigue and promote bone remodeling.

Biomechanical Advantages & Disadvantages

Advantages:
* Dynamic Stabilization: Allows for controlled fracture impaction.
* Less Stress Shielding: Compared to rigid fixation, it promotes bone loading.
* Well-established Technique: Long history of successful use, familiar to most orthopedic surgeons.
* Relatively Low Cost: Compared to some newer implants.

Disadvantages:
* Not Suitable for All Fractures: Poor for reverse obliquity, subtrochanteric extension, or highly comminuted patterns where impaction cannot be controlled.
* Requires Intact Lateral Cortex: Failure to achieve a stable lateral buttress can lead to varus collapse.
* Risk of Cut-Out: Improper lag screw placement (too superior, too anterior, too shallow) or poor bone quality can lead to the screw cutting through the femoral head. Optimal placement is key (tip-apex distance).
* Over-Compaction/Shortening: Excessive collapse can lead to significant leg length discrepancy.

Pathologic Bone Considerations

When dealing with pathologic fractures due to metastatic disease, the biomechanical landscape changes significantly:
* Compromised Bone Quality: Lytic lesions create areas of significant bone loss and structural weakness. Blastic lesions, while appearing dense, may represent immature, disorganized bone that is mechanically inferior to healthy cortical bone. Mixed lesions present a combination of these challenges.
* Reduced Screw Purchase: Both lytic and blastic lesions can compromise the ability of the lag screw and cortical screws to achieve adequate purchase, increasing the risk of cut-out, pull-out, and hardware failure.
* Increased Risk of Varus Collapse: Especially with extensive posteromedial cortical destruction by tumor, the ability to achieve and maintain medial buttress is challenging, predisposing to varus malunion or collapse.
* Need for Augmentation: Due to compromised bone stock, cement augmentation (polymethylmethacrylate, PMMA) into the tumor cavity is frequently considered to improve construct stability and prevent mechanical failure. This creates an immediate rigid construct, but also means the dynamic nature of SHS is effectively negated in that region.
* Tumor Progression: The underlying disease process can continue, potentially leading to further bone destruction around the implant, re-fracture, or delayed healing.

In summary, while the SHS remains a viable option for select stable intertrochanteric pathologic fractures, the altered bone mechanics necessitate meticulous pre-operative planning, precise surgical technique, and often consideration of adjunctive measures like cement augmentation to mitigate the increased risks of failure.

Indications & Contraindications

The decision to use a sliding hip screw plate for a hip fracture, especially in the context of metastatic disease, requires careful consideration of fracture morphology, bone quality, patient factors, and the oncologic status.

General Indications for SHS

• Stable Intertrochanteric Fractures:
  • AO/OTA 31-A1 (simple two-part) fractures.
  • AO/OTA 31-A2.1 (multifragmentary, lesser trochanter fragment, but stable medial buttress).
• Selected Unstable Intertrochanteric Fractures:
  • AO/OTA 31-A2.2 (multifragmentary, posteromedial comminution, but achievable stable reduction and good bone quality). These require careful reduction to achieve an acceptable medial buttress.
• Good Bone Stock: Adequate bone density to allow for secure screw purchase and prevent cut-out.

Specific Considerations for Pathologic Fractures

The management of pathologic fractures or impending pathologic fractures of the proximal femur with SHS is complex and often driven by the patient's oncologic prognosis and functional goals.

• Impending Pathologic Fractures: Prophylactic fixation is indicated for lesions meeting specific criteria (e.g., Mirels score $\ge 9$, lesion > 2.5 cm or > 50% cortical destruction on X-ray, intractable pain despite radiation). An SHS may be considered for impending intertrochanteric lesions if the remaining bone quality is sufficient to support the construct.
• Actual Pathologic Fractures: The primary goal is pain relief, restoration of function, and allowing early mobilization. SHS is a viable option for stable intertrochanteric patterns in patients with a limited life expectancy where a less invasive procedure is desired, or in stable lesions with good remaining bone stock where cement augmentation can provide immediate stability.

The Crucial Biopsy Discussion: "Do you always biopsy hip metastases first?"

This question is central to managing suspected pathologic fractures. The answer is not always , but the decision is nuanced and multifactorial.

• When Pre-operative Biopsy is Mandatory (or strongly recommended):

  • Unknown Primary Malignancy: If the patient presents with a suspected pathologic fracture and has no known history of cancer, a biopsy is essential for definitive diagnosis and to guide subsequent oncologic management. This differentiates between primary bone tumors (benign or malignant), metastatic disease, or other conditions.
  • Atypical Presentation: If the imaging characteristics of the lesion are unusual for known metastases, or if there's suspicion of a benign aggressive lesion (e.g., giant cell tumor, aneurysmal bone cyst) or a primary bone sarcoma (e.g., osteosarcoma, chondrosarcoma).
  • Need for Targeted Therapy: For certain cancers, specific molecular markers obtained from biopsy are crucial for selecting targeted systemic therapies (e.g., HER2 status in breast cancer, EGFR mutations in lung cancer).
  • Prognostic Information: Biopsy can provide valuable information about tumor type, grade, and aggressiveness, which impacts prognosis and treatment planning.

• When Biopsy Can Be Deferred or Performed Intraoperatively (in select cases):

  • Known Primary Malignancy: If the patient has a well-documented history of a primary cancer known to metastasize to bone (e.g., breast, prostate, lung) and the hip lesion has typical radiographic features of metastasis, a pre-operative biopsy may be deferred, especially if the fracture requires urgent stabilization.
  • Urgency of Fixation: For severe, displaced, or painful pathologic fractures, immediate stabilization may take precedence to alleviate pain and facilitate early mobilization. Delaying surgery for a biopsy and its results could prolong suffering and increase complication risks.
  • High Surgical/Biopsy Risk: In frail patients with significant comorbidities, undergoing an additional biopsy procedure may pose undue risk.
  • Intraoperative Biopsy: If a pre-operative biopsy was not performed, an intraoperative biopsy can be considered, especially if the primary diagnosis is still uncertain but fixation is urgent. This involves obtaining tissue samples during the fixation procedure. However, the quality of intraoperative samples may be less optimal than a dedicated image-guided biopsy, and contamination issues for culture if infection is a differential must be considered.
  • Prior Biopsy or Known Biopsy-Proven Metastasis: If the lesion has already been biopsied or is clearly a progression of a previously biopsied metastatic site.

The decision for biopsy should always involve a multidisciplinary discussion with medical oncology, radiation oncology, and potentially pathology, balancing the need for diagnosis with the urgency of fracture stabilization and the overall patient prognosis.

Contraindications for SHS

• Reverse Obliquity Fractures (AO/OTA 31-A3): This is a strong contraindication . The lateral cortex is in tension, leading to high rates of varus collapse, lag screw cut-out, and plate failure. Intramedullary nailing (IMN) is the preferred treatment.
• Subtrochanteric Extension: If the fracture line extends significantly into the subtrochanteric region, an SHS provides inadequate fixation. IMN is typically indicated.
• Severe Comminution: Especially if there is extensive comminution of the lateral femoral cortex or severe medial instability (e.g., 31-A2.3 type), preventing stable purchase of the side plate or reliable impaction.
• Extensive Lytic Lesions: When the tumor has caused significant bone destruction around the proposed lag screw path or at the plate fixation sites, rendering secure fixation impossible even with cement augmentation. IMN may bypass the region of poor bone.
• Failed Reduction: If an anatomical or acceptable reduction cannot be achieved, the SHS is unlikely to provide stable fixation.
• Active Infection: Absolute contraindication for any elective implant surgery.

Table: Operative vs. Non-Operative Indications for Hip Fractures (with Pathologic Considerations)

Note: SHS is generally preferred for stable intertrochanteric patterns. For reverse obliquity, subtrochanteric extension, or highly comminuted unstable patterns, intramedullary nailing (IMN) is generally the preferred operative treatment.

Pre-Operative Planning & Patient Positioning

Meticulous pre-operative planning is critical for successful SHS fixation, especially in pathologic fractures, to optimize outcomes and minimize complications.

Imaging Studies

1. Radiographs:
   • AP pelvis, AP hip, Lateral hip: Essential to define fracture pattern, degree of comminution, and bone quality. The "true lateral" view is crucial for determining the anterior-posterior position of the lag screw.
   • Full-length femur X-rays: In cases of metastatic disease, necessary to rule out skip lesions or other unstable lesions along the femoral shaft.
2. Computed Tomography (CT) Scan:
   • High-resolution CT of the hip: Indispensable for detailed assessment of fracture comminution (especially posterior/medial), cortical integrity, and the extent of tumor involvement (lytic vs. blastic, intraosseous vs. cortical breach). Provides crucial information for implant selection and potential need for cement augmentation.
   • CT chest/abdomen/pelvis: For staging the primary malignancy or detecting other metastatic sites if the primary is unknown.
3. Magnetic Resonance Imaging (MRI):
   • MRI of the proximal femur: Essential for evaluating soft tissue extension of the tumor, marrow involvement, and identifying occult lesions or skip metastases that may influence the length of the implant or need for wider resection margins if a primary tumor is suspected.
4. Positron Emission Tomography (PET) Scan:
   • PET-CT: Useful for whole-body staging in known primary malignancies to detect additional metastatic sites and assess metabolic activity of the lesion, which can inform prognosis and systemic therapy decisions.

Medical Workup & Oncology Consult

1. Medical Optimization: Comprehensive assessment of patient comorbidities (cardiac, pulmonary, renal, endocrine). Optimization of chronic conditions (diabetes, hypertension) is paramount. Anesthetic risk stratification (ASA score) is crucial.
2. Nutritional Status: Assess for malnutrition, common in cancer patients, which can impair wound healing and increase infection risk.
3. Hematologic Workup: Baseline complete blood count, coagulation profile. Assess for anemia, thrombocytopenia (due to marrow involvement or chemotherapy), and coagulopathy. Cross-match blood if significant blood loss is anticipated.
4. Oncology/Radiation Oncology Consult:
   • Biopsy Decision: Crucial for deciding if and when a biopsy is needed. This multidisciplinary discussion will determine the urgency of fixation vs. diagnostic imperative.
   • Systemic Therapy: Coordinate surgery with planned chemotherapy, targeted therapy, or immunotherapy schedules.
   • Radiation Therapy: Plan for post-operative radiation therapy if indicated for local tumor control, especially if intralesional curettage was performed or if surgical margins are positive (though less common for SHS for purely palliative/fixation goals).
   • Prognosis: Obtain a realistic assessment of patient's life expectancy, which guides the choice between palliative fixation (SHS often fits this) and more definitive reconstruction (e.g., tumor endoprosthesis, which is beyond the scope of SHS but relevant for young patients with long prognosis).

Biopsy Planning (If Indicated)

• Image-Guided Core Needle Biopsy: Preferred method for most suspected metastatic lesions. Performed by interventional radiology. Ensures sampling of representative tissue while minimizing contamination.
• Open Biopsy: Reserved for cases where core needle biopsy is non-diagnostic or technically challenging.
• Biopsy Tract Planning: If there is any suspicion of a primary bone sarcoma, the biopsy tract must be planned so that it can be completely excised during definitive surgery, to prevent tumor seeding. This is less critical for metastatic disease where the goal is typically palliation, but still good surgical oncology principle.

Implant Selection & Templating

1. Implant Type: Confirm SHS is the appropriate implant (vs. IMN or arthroplasty) based on fracture pattern, bone quality, and tumor extent.
2. Lag Screw Length and Diameter: Determined by femoral head size and subchondral distance. Templating helps ensure the lag screw will be placed approximately 1 cm from the articular surface. The largest diameter screw compatible with the reamer is generally preferred for optimal purchase.
3. Side Plate Length and Barrel Angle: The plate must span the fracture with at least 4 cortices of screw fixation distally. The barrel angle (e.g., 135°, 140°, 145°) is chosen to match the neck-shaft angle, aiming for a central-inferior position of the lag screw in the femoral head. Templating on AP X-rays using a contralateral hip (if available) or the fractured hip helps determine the appropriate angle.
4. Cement Augmentation: If significant lytic destruction or osteoporosis is present, plan for polymethylmethacrylate (PMMA) augmentation. This can be pre-mixed and delivered via syringe or directly injected into the cavity after curettage.

Patient Positioning

• Fracture Table: The patient is typically positioned supine on a fracture table. This allows for controlled traction, internal rotation, and abduction/adduction of the limb, which are crucial for fracture reduction.
• Well-Padded: All pressure points (heels, sacrum, perineum, ulnar nerve) must be meticulously padded to prevent pressure sores or nerve palsies.
• C-arm Access: Ensure unrestricted access for the fluoroscopic C-arm in both AP and lateral planes. The unaffected leg should be flexed, abducted, and positioned in a leg holder to allow for C-arm movement.
• Pelvic Tilt: The pelvis must be level and square to avoid rotational errors in intraoperative imaging and subsequent screw placement. A bump under the ipsilateral hip can help prevent external rotation.

Detailed Surgical Approach / Technique

The surgical technique for SHS insertion for an intertrochanteric fracture involves a lateral approach to the proximal femur. This detailed step-by-step guide is for a standard SHS; modifications for pathologic fractures (e.g., curettage, cement augmentation) are noted.

Anesthesia & Prophylaxis

• Anesthesia: General or regional (spinal/epidural) anesthesia is commonly used.
• Antibiotic Prophylaxis: Administer intravenous broad-spectrum antibiotics (e.g., cefazolin) within 60 minutes prior to incision, and continue for 24 hours post-operatively.
• DVT Prophylaxis: Initiate DVT prophylaxis (pharmacological and/or mechanical) pre-operatively or immediately post-operatively, based on institutional guidelines and patient risk factors.

Incision

1. Skin Incision: Make a longitudinal incision, typically 10-15 cm in length, centered over the greater trochanter and extending distally along the line of the femoral shaft. The proximal extent should allow adequate visualization of the greater trochanter and proximal femoral shaft.

Dissection

1. Subcutaneous Tissue: Incise subcutaneous fat down to the fascia lata.
2. Fascia Lata: Incise the fascia lata longitudinally in line with the skin incision, beginning just superior to the greater trochanter and extending distally.
3. Vastus Lateralis: The vastus lateralis muscle will be identified deep to the fascia lata.
   • Internervous Plane: The approach dissects through the plane between the tensor fascia lata and the vastus lateralis, or directly splits the vastus lateralis, exposing the lateral femoral cortex. The vastus lateralis is supplied by the femoral nerve (L2-L4).
   • Elevation: Elevate the vastus lateralis muscle anteriorly from the lateral femoral cortex in a subperiosteal plane. Use an electrocautery or periosteal elevator. Preserve the blood supply to the vastus lateralis as much as possible to minimize muscle necrosis. Create a tunnel large enough to accommodate the side plate flush against the bone.
   • Pathologic Bone: In cases of pathologic fractures, there may be tumor involvement of the soft tissues or a cortical breach. Careful dissection is required to identify the extent of disease and avoid unnecessary tumor spill if a biopsy was deferred. If an intraoperative biopsy is performed, ensure a clean biopsy technique.

Reduction

1. Traction: Apply traction on the fracture table to achieve length.
2. Rotation: Internally rotate the limb to correct external rotation deformity.
3. Abduction/Adduction: Adjust abduction/adduction as needed to align the fragments.
4. Fluoroscopic Confirmation: Obtain AP and true lateral fluoroscopic views to confirm acceptable reduction. The goal is an anatomical reduction; however, for intertrochanteric fractures, an acceptable reduction often involves slight valgus alignment and good apposition of fragments. Check for fracture gap or malalignment.
5. Temporary Fixation (optional): K-wires may be used to temporarily hold reduction, especially in highly unstable patterns, but are often not needed with good traction.

Guide Pin Placement

1. Entry Point:
   • Identify the guide pin entry point on the lateral femoral cortex. It is typically inferior to the vastus ridge, at the junction of the middle and distal thirds of the greater trochanter, and slightly anterior to the mid-lateral line of the femur. This position aligns with the desired path into the femoral head.
   • Make a small stab incision at this point with a scalpel, and use a drill bit to make an initial cortical hole through the lateral cortex.
2. Aiming Device: Attach an appropriate aiming device (e.g., triple reamer, direct measurement guide) to the entry point.
3. Guide Pin Insertion:
   • Insert the guide pin through the aiming device and advance it into the femoral head.
   • Target Position: The ideal position for the guide pin (and subsequently the lag screw) is:
     • AP view: Central-inferior quadrant of the femoral head. This provides maximum bone stock in the calcar region for support.
     • Lateral view: Centrally located in the femoral head.
   • Depth: Advance the guide pin to within 1 cm of the subchondral bone of the femoral head. Avoid penetrating the articular cartilage.
   • Fluoroscopic Control: Continuously monitor guide pin placement with AP and lateral fluoroscopy. Ensure the pin is not too anterior, posterior, superior, or inferior.
4. Tip-Apex Distance (TAD): Crucial for minimizing cut-out. The sum of the distances from the tip of the lag screw to the apex of the femoral head on the AP and lateral views should be less than 25 mm. A properly placed guide pin ensures optimal TAD.
5. Measure Pin Length: Determine the correct lag screw length using a calibrated measuring device over the guide pin.

Reaming & Tapping

1. Reaming: Over-ream the guide pin with the appropriate reamer (e.g., triple reamer, stepped reamer) to create a channel for the lag screw barrel. Ensure the reamer is advanced to the measured depth.
2. Tapping (optional): If the bone is very dense, tap the reamed channel to facilitate lag screw insertion and prevent stripping. For osteoporotic or pathologic bone, tapping may not be necessary or even detrimental as it can further compromise bone purchase.

Lag Screw Insertion

1. Cannulated Lag Screw: Insert the cannulated lag screw over the guide pin.
2. Positioning: Advance the lag screw until its threads are fully engaged within the femoral head, and the barrel portion is flush with the lateral femoral cortex. Ensure the screw is not over-inserted (penetrating articular cartilage) or under-inserted (insufficient purchase).
3. Compression (optional): A compression screw can be inserted into the lag screw to achieve additional fracture impaction, if desired. This should be done carefully to avoid excessive shortening or over-compression in unstable fractures.
4. Remove Guide Pin: Once the lag screw is securely in place, remove the guide pin.

Plate Application & Fixation

1. Attach Side Plate: Select the appropriate side plate (barrel angle matching neck-shaft angle). Slide the plate barrel over the lag screw.
2. Impact Plate: Impact the side plate onto the lateral femoral cortex until it sits flush against the bone. Ensure the plate is correctly aligned with the femoral shaft.
3. Secure Plate:
   • Using drill guides, drill holes for cortical screws through the plate into the femoral shaft.
   • Measure the length for each screw and insert appropriate cortical screws (typically at least 4 cortices distal to the fracture, ensuring bicortical fixation where possible).
   • Cement Augmentation (for pathologic fractures/osteoporosis): If planned, curette any visible tumor from the fracture site or defect prior to plate fixation. Inject PMMA into the lytic cavity through the lag screw hole or separate drill holes before inserting the cortical screws. This provides immediate stability and fills the defect. Allow the cement to partially polymerize before tightening screws.
4. Final Fluoroscopic Check: Obtain final AP and lateral views to confirm:
   • Anatomical reduction.
   • Optimal lag screw position (TAD < 25 mm).
   • Correct plate position and screw length.
   • Absence of articular penetration.
   • Presence of cement if used.

Wound Closure

1. Irrigation: Thoroughly irrigate the wound with sterile saline.
2. Hemostasis: Achieve meticulous hemostasis.
3. Drain (optional): A drain may be inserted deep to the fascia lata, particularly if significant bleeding is anticipated or extensive curettage of a tumor was performed.
4. Layered Closure: Close the vastus lateralis over the plate, then the fascia lata, subcutaneous tissue, and skin using appropriate sutures.

Complications & Management

Complications following SHS fixation can range from implant-related issues to biological failures and are often exacerbated in the context of pathologic fractures due to compromised bone quality and ongoing disease.

Table: Common Complications, Incidence, and Salvage Strategies

General Management Principles

• Prompt Diagnosis: Early identification of complications is crucial for effective management.
• Multidisciplinary Approach: Especially for pathologic fractures, involving oncology, radiation oncology, infectious disease, and pain management teams is essential for holistic patient care.
• Patient Factors: Patient's age, functional demands, overall health status, and life expectancy significantly influence the choice of salvage strategy. For elderly, frail patients with limited life expectancy, a less aggressive, palliative approach may be most appropriate.
• Prophylactic Measures: Correct surgical technique, optimal lag screw placement (TAD < 25mm), and appropriate implant selection are the best defenses against many complications. For pathologic fractures, cement augmentation significantly reduces the risk of mechanical failure.

Post-Operative Rehabilitation Protocols

Post-operative rehabilitation following SHS fixation for intertrochanteric fractures aims to restore function, minimize complications, and facilitate a return to activities of daily living. Protocols must be tailored to the individual patient, especially considering factors like bone quality, fracture stability, comorbidities, and the presence of underlying malignancy.

Immediate Post-Operative Period (Day 0-7)

1. Pain Management: Aggressive multi-modal pain control (opioids, NSAIDs, acetaminophen, nerve blocks) to facilitate early mobilization.
2. DVT Prophylaxis: Continue pharmacological (e.g., low molecular weight heparin) and mechanical (e.g., pneumatic compression devices) prophylaxis.
3. Early Mobilization:
   • Day 0-1: Out of bed to a chair with assistance, initiation of gentle ankle pumps, quadriceps sets, and gluteal sets.
   • Day 1-3: Standing at bedside with assistance, initiate protected weight-bearing.
4. Wound Care: Monitor incision for signs of infection (erythema, swelling, discharge). Dressing changes as per institutional protocol.

Weight-Bearing Status

The most critical aspect of SHS rehabilitation. This decision is based on:
* Fracture Stability: Stable (A1, A2.1) vs. unstable (A2.2) reduction.
* Bone Quality: Osteoporotic vs. normal, and extent of lytic destruction in pathologic fractures.
* Cement Augmentation: If cement was used, immediate stability is enhanced, potentially allowing earlier weight-bearing.
* Patient Compliance: Ability to adhere to weight-bearing restrictions.

General Guidelines:

• Stable Fractures / Good Bone Quality / Cement Augmentation:
  • Touch-down weight-bearing (TDWB) or Partial Weight-Bearing (PWB) (25-50% body weight): Typically initiated immediately or within the first week, using a walker or crutches.
  • Progression: Gradually advance weight-bearing to weight-bearing as tolerated (WBAT) over 6-12 weeks, guided by pain and radiographic signs of healing.
• Unstable Fractures / Poor Bone Quality / No Cement Augmentation / Pathologic Fractures with Extensive Lysis:
  • Non-weight-bearing (NWB) or TDWB: Often maintained for 6-8 weeks to allow initial callus formation.
  • Progression: Carefully advance to PWB, then WBAT, often over 12-16 weeks or longer, with close radiographic monitoring.
  • Pathologic Fractures: May require prolonged protected weight-bearing or even permanent assistive device use if bone healing is expected to be slow or incomplete due to underlying disease or radiation.

Physical Therapy (PT)

• Early Phase (0-6 weeks):
  • Range of Motion (ROM): Gentle passive and active-assisted ROM for hip and knee (flexion, extension, abduction, adduction within pain limits).
  • Strengthening: Isometrics (quadriceps sets, gluteal sets, hamstring sets). Active ankle pumps.
  • Gait Training: Instruction on safe transfers, use of assistive devices (walker, crutches), and protected weight-bearing ambulation. Stair training as appropriate.
• Intermediate Phase (6-12 weeks):
  • Progression of ROM: Advance to full active ROM as tolerated.
  • Progression of Strengthening: Introduce light resistance exercises (resistance bands, light weights) for hip abductors, adductors, flexors, extensors, and knee musculature. Core strengthening.
  • Balance & Proprioception: Standing balance exercises, single-leg stance.
  • Wean Assistive Devices: Gradually reduce reliance on walker/crutches as strength, balance, and pain allow.
• Advanced Phase (12+ weeks):
  • Return to Function: Continue progressive strengthening, endurance training.
  • Functional Activities: Incorporate activities specific to patient's goals (e.g., return to work, hobbies).
  • Sports-specific training: For younger, active patients.
  • Pathologic Fractures: Emphasis on maintaining maximal functional independence within the context of their disease, often with ongoing pain management strategies.

Occupational Therapy (OT)

• Activities of Daily Living (ADLs): Training on compensatory strategies for dressing, bathing, toileting, and household tasks.
• Adaptive Equipment: Prescription and training for use of assistive devices (long-handled reachers, sock aids, raised toilet seats) to maintain independence.
• Home Safety Assessment: Recommendations for modifying the home environment to prevent falls.

Follow-up

• Clinical Assessment: Regular follow-up appointments (e.g., 2 weeks, 6 weeks, 3 months, 6 months, 1 year) to assess pain, wound healing, limb length, ROM, and functional status.
• Radiographic Assessment: Repeat AP and lateral X-rays at each follow-up to monitor fracture healing, implant integrity, and detect potential complications (e.g., cut-out, non-union, hardware failure). For pathologic fractures, surveillance for local tumor progression or re-fracture is crucial.
• Oncologic Surveillance: For pathologic fractures, continue regular oncologic follow-up, including systemic imaging (CT/PET) as per the primary cancer's surveillance protocol.

Summary of Key Literature / Guidelines

The management of intertrochanteric fractures, particularly those arising from metastatic disease, is supported by a robust body of literature and established clinical guidelines.

AOTrauma Guidelines

AOTrauma principles emphasize stable internal fixation, anatomical reduction, and early mobilization. For intertrochanteric fractures, AOTrauma generally recommends:
* Stable Patterns (AO/OTA 31-A1, 31-A2.1): SHS is a well-established and effective treatment, promoting controlled collapse and load sharing.
* Unstable Patterns (AO/OTA 31-A2.2, 31-A2.3): While SHS can be used in some A2.2 fractures if a stable medial buttress can be achieved, there is a growing trend towards intramedullary nailing (IMN) due to its superior biomechanical stability in highly comminuted patterns, especially those with lateral wall compromise.
* Reverse Obliquity Fractures (AO/OTA 31-A3): IMN is the preferred implant due to the biomechanical disadvantages of SHS in these fractures, which lead to high rates of failure.

NCCN/AAOS Guidelines for Pathologic Fractures

The National Comprehensive Cancer Network (NCCN) and American Academy of Orthopaedic Surgeons (AAOS) provide comprehensive guidelines for the management of bone metastases and pathologic fractures. Key tenets include:
* Multidisciplinary Approach: Emphasizes collaboration between orthopedic oncology, medical oncology, radiation oncology, diagnostic radiology, and pathology. This is paramount for appropriate patient selection, biopsy decisions, and integrated treatment planning.
* Timing of Biopsy:
* Unknown Primary: A pre-operative tissue biopsy is considered mandatory for definitive diagnosis, differentiation from primary bone tumors, and guiding systemic therapy. This is usually an image-guided core needle biopsy.
* Known Primary: If the patient has a known primary malignancy with typical radiographic features of metastasis, a pre-operative biopsy may be omitted to expedite urgent fixation for pain or impending fracture, especially in patients with limited life expectancy. Intraoperative biopsy can be considered in equivocal cases.
* Prophylactic Fixation: Indicated for impending fractures, commonly assessed by the Mirels score. Lesions with a Mirels score of $\ge 9$ are generally considered for prophylactic stabilization. This can significantly reduce pain and prevent more complex actual fractures.
* Implant Selection for Pathologic Fractures:
* Long-term vs. Palliative: The choice of implant depends on the patient's prognosis. For patients with good prognosis, more durable and reconstructive options (e.g., tumor endoprosthesis, extensive reconstruction) may be considered. For limited prognosis, fixation for pain relief and mobility takes precedence.
* SHS vs. IMN for Pathologic Femoral Fractures:
* IMN is generally favored for pathologic subtrochanteric fractures and reverse obliquity intertrochanteric fractures, as it bypasses the tumor-involved segment and provides more robust stability.
* SHS can be a suitable option for stable intertrochanteric pathologic fractures, especially if cement augmentation is used to enhance stability within lytic defects. Its role is often more pronounced in palliative scenarios due to its established efficacy, relative ease of insertion compared to some IMNs, and ability to be combined with cement.
* Adjuvant Therapy: Radiation therapy is routinely recommended post-operatively for metastatic lesions (either actual or impending fractures) to provide local tumor control and reduce the risk of further bone destruction. Systemic therapies (chemotherapy, targeted therapy, immunotherapy, hormonal therapy) are crucial for managing the underlying metastatic disease.

Evidence for Biopsy First

The literature strongly supports performing a biopsy prior to definitive fixation for any suspected pathologic fracture where the primary malignancy is unknown. Studies have shown that a significant percentage of these lesions (ranging from 10-30%) may turn out to be a primary bone tumor, benign aggressive lesion, or a different type of metastasis than initially suspected. Incorrect diagnosis can lead to inappropriate oncologic staging, inadequate treatment, and worse outcomes.
* Delaying fixation for a few days to obtain a biopsy result typically does not significantly worsen the prognosis or functional outcome, but provides invaluable diagnostic clarity.
* Intraoperative biopsy is an alternative, but it carries limitations in terms of sample quality, potential for contamination, and may not always yield a definitive diagnosis, necessitating a second procedure.

SHS vs. IMN for Pathologic Proximal Femoral Fractures

While IMN has gained favor for its biomechanical advantages in unstable and subtrochanteric fractures, the SHS still holds a niche for certain pathologic fractures:
* SHS Advantages: Established technique, controlled impaction (if bone quality allows), effective with cement augmentation for contained lytic lesions, often less technically demanding than complex IMN for some surgeons.
* IMN Advantages: Load sharing with less hardware stress, more stable for subtrochanteric extension, reverse obliquity, and highly comminuted fractures, especially with cephalomedullary nails. IMNs often provide greater stiffness and better bypass capabilities for more extensive lesions.

The choice ultimately depends on the specific fracture pattern, extent of tumor involvement, bone quality, surgeon preference, and patient-specific factors (e.g., prognosis, functional goals). Cement augmentation is a critical adjunct for both SHS and IMN in pathologic fractures to enhance implant purchase and construct stability in compromised bone.